Acadia closes on $150M FDA voucher sale

by
Contributor since / Followers

1 month ago

Acadia Pharmaceuticals (NASDAQ:ACAD) said it has closed on the sale of its FDA Rare Pediatric Disease Priority Review Voucher, or PRV, for $150M.
The biotech company was granted the PRV in March 2023 after receiving FDA approval for its drug

Tags: ACAD